Oncology RCC       

FOI REFERENCE: 24427  FOI DATE: 11^th October 2024     

Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage) :  

• Avelumab + Axitinib                                                    2
• Axinitib                                                                        3
• Cabozantinib                                                               13
• Everolimus                                                                  0
• Lenvatinib + Everolimus                                             0
• Lenvatinib + Pembrolizumab                                      12
• Nivolumab monotherapy                                             14
• Nivolumab + Cabozantinib                                          0
• Nivolumab + Ipilimumab                                             0
• Pazopanib                                                                   18
• Pembrolizumab monotherapy                                     19
• Pembrolizumab + Axitinib                                           0
• Radiotherapy only                                                      
• Sunitinib                                                                      3
• Temsirolimus                                                              0
• Tivozanib                                                                    0
• Other active systemic anti-cancer therapy                 0
• Palliative care only                                                      71

Q2. In the last 3 months, how many patients have undergone full or partial nephrectomy (any of the following OPCS codes M02.1, M02.2, M02.3,M02.4, M02.5, M03.1, M03.9, M04.2, M10.1 or M10.4)? 17 Patients

Q3. In the last 3 months, how many patients have been initiated* on the following agents for treatment for Renal Cell Carcinoma?   

• Nivolumab (monotherapy)                                          2
• Nivolumab + Ipilimumab                                             0
• Nivolumab + Cabozantinib                                          0
• Avelumab + Axitinib                                                    0

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Q4. Does you trust participate in any clinical trials for the treatment of renal cell carcinoma? If so please provide the name of each trial and number of patients that are taking part?  No